# EDGAR Filing Document

**Accession Number:** 0001132317
**File Stem:** 0001104659-25-077544
**Filing Date:** 2025-8
**Character Count:** 10941
**Document Hash:** 341fbdd7710cf3f59294dbfe7e96ad07
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-077544.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0001104659-25-077544

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250813

**DATE AS OF CHANGE**: 20250813

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioCardia, Inc.
- **CENTRAL INDEX KEY:** 0000925741
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 232753988
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-52381
- **FILM NUMBER:** 251211514

**BUSINESS ADDRESS:**
- **STREET 1:** 320 SOQUEL WAY
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94085
- **BUSINESS PHONE:** 650-226-0123

**MAIL ADDRESS:**
- **STREET 1:** 320 SOQUEL WAY
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94085

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tiger X Medical, Inc.
- **DATE OF NAME CHANGE:** 20110616

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cardo Medical, Inc.
- **DATE OF NAME CHANGE:** 20081027

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CLICKNSETTLE COM INC
- **DATE OF NAME CHANGE:** 20000823
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SATTERFIELD THOMAS A JR
- **CENTRAL INDEX KEY:** 0001132317

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**MAIL ADDRESS:**
- **STREET 1:** 2609 CALDWELL MILL LN
- **CITY:** BIRMINGHAM
- **STATE:** AL
- **ZIP:** 35243

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Issuer:** BioCardia, Inc.

**Title of Class of Securities:** Common Stock, par value $0.001 per share

**CUSIP Number:** 09060U606

**Date of Event Which Requires Filing of this Statement:** 06/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Thomas A. Satterfield, Jr. | Names of Reporting Persons<br>Thomas A. Satterfield, Jr. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>153603.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>438541.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>153603.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>438541.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>592144.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>592144.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.9% | Percent of Class Represented by Amount in Row (9)<br>9.9% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** *Based on 5,801,224 shares of common stock of the issuer (the "Common Stock") outstanding as of August 8, 2025, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025. The Reporting Person may be deemed to beneficially own (i) 465,997 shares of Common Stock, and (ii) 283,912 warrants (the "Warrants") to purchase one share of Common Stock.  All of the Warrants are subject to a blocker provision pursuant to which the warrantholder does not have the right to exercise such Warrants if such exercise would result in beneficial ownership by the Reporting Person, together with his affiliates and any other persons acting as a group together with the Reporting Person, of more than 9.99% of the Common Stock outstanding upon such exercise, except for 17,317 Warrants that are not subject to any blocker provisions. Upon exercise, 59,262 of the Warrants (the "Sole Power Warrants"), all of which are subject to the blocker provision described above, would result in the issuance of shares of Common Stock over which the Reporting Person would have sole voting and dispositive power.

The 592,144 shares of Common Stock reported on this Schedule 13G as beneficially owned by the Reporting Person represent the 465,997 shares of Common Stock that the Reporting Person beneficially owns and 126,147 shares of Common Stock issuable upon exercise of Warrants, which collectively represent the Reporting Person's maximum beneficial ownership permissible under the applicable blocker provisions, or 9.99%. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 has been rounded down to 9.9%. This Schedule 13G assumes that the 126,147 Warrants so exercised would include all Warrants not subject to any blocker provisions and all Sole Power Warrants. If there were no limit on the Reporting Person's beneficial ownership of the issuer's Common Stock, the Reporting Person could be deemed to be the beneficial owner of an aggregate of 749,909 shares of Common Stock, representing 12.32% of the issuer's outstanding Common Stock (factoring in the exercise of such Warrants).

---

**Item 1(a). Name of Issuer:**
BioCardia, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
320 Soquel Way, Sunnyvale, CA 94085

**Item 2(a). Name of Person Filing:**
Thomas A. Satterfield, Jr.

**Item 2(b). Address of Principal Business Office:**
15 Colley Cove Drive
Gulf Breeze, Florida 32561

**Item 2(c). Citizenship:**
Incorporated by reference from Item 4 of the Cover Page.

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.001 per share

**Item 2(e). CUSIP Number:**
09060U606

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Incorporated by reference from Item 9 of the Cover Page.

**(b) Percent of class:**

Incorporated by reference from Item 11 of the Cover Page.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

Incorporated by reference from Item 5 of the Cover Page.

**(ii) Shared power to vote or to direct the vote:**

Incorporated by reference from Item 6 of the Cover Page.

**(iii) Sole power to dispose or to direct the disposition of:**

Incorporated by reference from Item 7 of the Cover Page.

**(iv) Shared power to dispose or to direct the disposition of:**

Incorporated by reference from Item 8 of the Cover Page.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 128,309 shares of Common Stock and 128,738 shares of Common Stock issuable upon exercise of Warrants are held by Tomsat Investment & Trading Co., Inc, a corporation wholly owned by Mr. Satterfield and of which he serves as President; 110,847 shares of Common Stock and 95,912 shares of Common Stock issuable upon exercise of Warrants are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and 130,000 shares of Common Stock are held by Caldwell Mill Opportunity Fund, LLC, a fund managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager.

Additionally, Mr. Satterfield has a limited power of attorney for voting and disposition purposes with respect to the following shares of Common Stock: Rebecca A. Satterfield (2,500 shares). Ms. Satterfield has the right to receive or the power to direct the receipt of the proceeds from the sale of her shares.

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Thomas A. Satterfield, Jr.**

**Date:** 08/13/2025

**By:** /s/ Thomas A. Satterfield, Jr.

**Name & Title:** Thomas A. Satterfield, Jr.